“So you think the FTO inhibition low dose avenue isn't a complete game changer? “
You took the words out of my mouth
@IndexInvestor!!
Thankyou
I wrote a long post yesterday , but lost it , wanting to emphasise this to anyone not getting it .
**Bisantrene is not only a straight anti- cancer cell activity drug.
As in :
1.
Bisantrene, a cancer cells killer - known .
With historically over 40 clinical trials showing its effectiveness—reconfirmed with the same high % of CR rates with the recent RAC Sheba trial .
• a good chemotherapy agent with high specificitiy to cancer cells , and through these over 40 extensive clinical trials , shows that bisantrene can lead to a Complete Response (“CR”) against a significant number and array of cancers .
Bisantrene can even lead many people into full remissions from cancers with other care ( Eg AML, with a suitable bone marrow / stem cell transplant )
• People alive today due to receiving Bisantrene as a very last-ditch , desperate treatment for refractory relapsed AML who were among the lucky few who could receive an exact matched donor bone marrow transplant from a sibling .
( note - All breast cancer and other trial participants from 80s/90s besides - due to their ages then , receiving bisantrene for a dire , refractory cancer - over 30 years later , are now all gone due to age and time . But bisantrene recipients did live longer than the anthracycline trial recipients in a notable breast cancer trial )
Which leads to that :
•Bisantrene has a spectrum of response activity similar to & can be said to be ‘
about’ equal to other anthracyclines .
With even broader activity where other anthracyclines may not have been completely successful.
*Most notably therefore- bisantrene is to be contrasted with Doxorubicin , commonly in use for direct cancer treatment.
What is wonderful is that bisantrene can be seen as a
better alternative to doxorubicin & others —
**as bisantrene does
not cause the cardiac damage notable with doxorubicin. **
Doxorubicin- is known for and dreaded due to its significant cardiac toxicity .
*Bisantrene does not lead people to end up in heart failure .* Certainly not with any level of high risk .
• And it appears Bisantrene can be effective , efficacious at
lowerdoses than doxorubicin! ( for the same anti- cancer cell, cancer fighting response )
•• And most particularly that - bisantrene can be used , where anthracyclines ( doxorubicin) have a good response against the patients cancer ,
but the patients have reached their “life -dose -limit” , or cannot tolerate doxorubicin anymore or at all.
( older patients, children, medically compromised esp with heart ot cardiac conditions , past cancer treatment )
Doxorubicin - is pretty much the standard of care for many patients ( especially for difficult , aggressive breast cancer patients notably )
It is called “The red devil” .
Doxorubicin is being used daily - as occurs all around the country literally every working day Monday- Friday in our hospital oncology wards ; as well as around the world, also every day of the week .
Bisantrene is apparently “orange “.
Bisantrene by comparison- is better tolerated than doxorubicin, Eg. with less nausea ?
Even some breast cancer patients didn’t lose their hair back in time in historical trials .
And the bisantrene patients ended up living longer - than the doxorubicin trial recipients , in the one contrast trial between doxorubicin with bisantrene. ( a trial that was designed to ‘show ‘ superiority of doxorubicin over bisantrene. )
Put a line under ALL of this.
Although it is All - true.
And even though most of us here, all probably - would wish to have bisantrene instead of doxorubicin, if this was what was on offer and we had a significant cancer .
We can judge it to be preferable , as alternative to existing standard of care if that were to be where bisantrene can be equally effective .
__________________________________________
What has made the difference , Now —
Is the
FTOprotein susceptibility , which Bisantrene seems to potentially exhibit .
* The FTO protein’s susceptibility to Bisantrene - makes an incredible ,
significant - difference !
AND this FTO Protein susceptibility with Bisantrene — ‘explains ‘ a Lot , about “
why” Bisantrene was so effective , with significant efficacy against such a broad range of cancers historically in trials and in the lab clinically .
This is where the great potential now exists for Race oncology with Bisantrene . The company must examine this closely and determine what to do with this and has therefore engaged the best consultants in the US to assist as well as overview the IND and trials planned .
**RAC - is a new prospect altogether since the very end of June this year.
Even draw a line under the shareprice even until then - and the resultant jump in shareprice to today’s levels then imo.
No one has missed anything yet I don’t think - we all can now watch to see how this unfolds .
•
Bisantrene -
A. Hopefully in the clinic soon in breast cancer trials for sure . AML R/R - Israel. An IND for AML in kids in the US. ( Race have the chance also to receive a PRV for Paediatric R/R / MRD+ve AML in the US. )
Without doubt the strategic pathways planned & they have the funds to start and be quite ok for money through the next 12 mths .
So sooner rather than later for trials - certainly I hope
B. However- the COH findings -and clinical work showing broad specificity which bisantrene has for
many cancers -
Bisantrene— much Much more excitingly , and which is the reason , for what seems to be cause of some delay to trials commencement , and the additional work being put in pre- clinically :
** Bisantrene was shown most recently , by the COH study , out of 250000 + agents, to be the No 1 inhibitor of the FTO protein which is strongly associated with many cancers that are difficult to treat and fully cure .
**The FTO protein is over- expressed in many refractory cancers .
Including : *Breast cancer , ovarian cancer , AML, bladder cancers , and many ,
many other cancers ..,
The FTO protein additionally - is involved with many difficult to treat cancers . Eg. ‘refractory ‘ ,
dire-
very advanced cancers , and “relapsed “ cancers .
Sound familiar ? ( ie. for how Bisantrene appears to have strong importance as a salvage chemotherapy treatment- to add to other drugs and gain a response and even a Complete Response .. where all else has failed to fully treat the patients cancer )
This is the Big thing - to think about , on top of the old paradigm Race - just of Bisantrene as a very “good” , “excellent” even ( all things considered ) = Alternate chemotherapeutic agent .
•Bisantrene has been known to have efficacy at lower doses against difficult to treat cancers .
•Bisantrene is known to have efficacy - in cancers which have specificity with the anthracyclines class of chemotherapy drugs ( Doxorubicin - standard of care - been around since the 1970s) and can do better where full remission was not achieved .
Bisantrene is an anthracene - related to the anthracyclines, with similar cancer responsiveness & potential with
less terrible side effects, and **no longterm co- morbidities **.
****
Bisantrenealso — seems to have the best response , great potential, **at low doses ** ~ against the cancer associated with expression of the FTO protein . *****
This is really , greatly ,
significant.